# Ozekibart (INBRX-109) PDUFA Event: Unresectable or metastatic conventional chondrosarcoma

Canonical URL: https://biopharmsignal.com/pdufa-calendar/INBX/ozekibart-conventional-chondrosarcoma

Ticker: INBX

Company: Inhibrx

Event date: 2027-04-14

Event type: FDA Decision

Stage: PDUFA

Result: Pending

Application type: BLA

FDA decision expected. FDA set April 14, 2027 as the PDUFA goal date for the ozekibart BLA in conventional chondrosarcoma.

## Event Timeline

### April 14, 2027 — FDA decision expected

FDA set April 14, 2027 as the PDUFA goal date for the ozekibart BLA in conventional chondrosarcoma.

[Inhibrx — BLA acceptance and PDUFA goal date](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000033/exhibit991-pressreleasebla.htm)

### June 17, 2026 — FDA accepted the BLA for review

FDA accepted Inhibrx's BLA for ozekibart for potential approval in patients with unresectable or metastatic conventional chondrosarcoma.

[Inhibrx — FDA acceptance announcement](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000033/exhibit991-pressreleasebla.htm)

### June 17, 2026 — ChonDRAgon study data supported the filing

The BLA was supported by efficacy and safety data from the Phase 2 ChonDRAgon study of ozekibart in conventional chondrosarcoma.

[Inhibrx — BLA filing support](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000033/exhibit991-pressreleasebla.htm)

## Related Pages

- INBX PDUFA calendar: https://biopharmsignal.com/pdufa-calendar/INBX.md

- INBX company profile: https://biopharmsignal.com/company/INBX.md

- PDUFA calendar: https://biopharmsignal.com/pdufa-calendar.md

## Related News

- 2026-09-08 — Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study: https://biopharmsignal.com/news/INBX/inhibrx-s-inbrx-106-nearly-doubles-response-rate-and-achieves-interim-median-pfs-2cfa641f.md

- 2026-09-04 — Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study: https://biopharmsignal.com/news/INBX/inhibrx-to-host-webcast-presentation-to-provide-primary-endpoint-results-for-inb-14d23ad0.md

- 2026-08-13 — Inhibrx Reports Second Quarter 2026 Financial Results: https://biopharmsignal.com/news/INBX/inhibrx-reports-second-quarter-2026-financial-results-46b64780.md

- 2026-07-16 — Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million: https://biopharmsignal.com/news/INBX/inhibrx-announces-amended-loan-agreement-with-oxford-finance-expanding-total-fac-d29cd85b.md

- 2026-06-15 — Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma: https://biopharmsignal.com/news/INBX/inhibrx-announces-u-s-fda-acceptance-of-bla-for-ozekibart-in-patients-with-conve-d0380d86.md